According to the Zhitong Finance App, Teyi Pharmaceutical (002728.SZ) released its 2022 annual performance forecast. The net profit attributable to shareholders of listed companies for the full year is 173 million yuan to 183 million yuan, an increase of 36.31% to 44.19% over the previous year.

During the reporting period, net profit attributable to shareholders of listed companies and net profit after deducting non-recurring profit and loss increased significantly compared to the same period of the previous year. The main reason was that since the third quarter, the company adjusted its marketing strategies and plans, increased its market development and promotion efforts, and achieved good results. In particular, in the fourth quarter, after the release of the epidemic, the company increased the production and market supply of drugs for the prevention and control of the epidemic, and sales of related drugs such as cough tablets increased significantly over the same period, leading to an increase in revenue.